New Launch6 Jul 2026, 08:38 am
Glenmark Pharma USA Launches Olanzapine Injection
AI Summary
Glenmark Pharmaceuticals Inc., USA has announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial. This product is bioequivalent and therapeutically equivalent to Zyprexa® IntraMuscular Injection 10 mg/vial. The launch is part of Glenmark's strategy to expand its injectables portfolio and strengthen its presence in the institutional channel. The reference drug, Zyprexa® IntraMuscular Injection, had annual sales of approximately $25.4 million for the 12 months ending May 2026, according to IQVIA® sales data. This launch aims to provide affordable treatment options to patients and healthcare providers.
Key Highlights
- Glenmark Pharmaceuticals USA launches Olanzapine for Injection.
- Product is bioequivalent to Zyprexa® IntraMuscular Injection.
- Aims to grow injectables portfolio and institutional channel presence.
- Reference drug market achieved $25.4 million in annual sales.
- Focus on providing affordable treatment options.
Price Impact
More from GLENMARK